Wipfli Financial Advisors LLC bought a new stake in shares of Insulet Co. (NASDAQ:PODD – Get Rating) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 209 shares of the medical instruments supplier’s stock, valued at approximately $48,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of PODD. SeaCrest Wealth Management LLC bought a new stake in Insulet during the second quarter worth about $26,000. Washington Trust Advisors Inc. grew its stake in shares of Insulet by 25.0% in the 2nd quarter. Washington Trust Advisors Inc. now owns 260 shares of the medical instruments supplier’s stock worth $57,000 after buying an additional 52 shares during the last quarter. Allworth Financial LP increased its position in Insulet by 3,362.5% during the 2nd quarter. Allworth Financial LP now owns 277 shares of the medical instruments supplier’s stock valued at $60,000 after buying an additional 269 shares in the last quarter. Ellevest Inc. raised its stake in Insulet by 64.9% during the second quarter. Ellevest Inc. now owns 475 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 187 shares during the last quarter. Finally, Dakota Wealth Management purchased a new position in Insulet during the first quarter valued at $213,000.
Insider Transactions at Insulet
In related news, SVP Dan Manea sold 200 shares of the stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $294.62, for a total value of $58,924.00. Following the completion of the sale, the senior vice president now directly owns 3,158 shares of the company’s stock, valued at approximately $930,409.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, SVP Dan Manea sold 200 shares of the company’s stock in a transaction on Friday, November 18th. The shares were sold at an average price of $294.62, for a total value of $58,924.00. Following the completion of the transaction, the senior vice president now owns 3,158 shares of the company’s stock, valued at approximately $930,409.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael P. Spears sold 13,658 shares of the firm’s stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $308.99, for a total value of $4,220,185.42. Following the sale, the senior vice president now directly owns 8,792 shares in the company, valued at $2,716,640.08. The disclosure for this sale can be found here. Insiders have sold 28,858 shares of company stock valued at $8,507,309 over the last quarter. 0.90% of the stock is currently owned by company insiders.
Insulet Stock Performance
Insulet (NASDAQ:PODD – Get Rating) last posted its quarterly earnings data on Thursday, November 3rd. The medical instruments supplier reported $0.45 EPS for the quarter, topping the consensus estimate of $0.17 by $0.28. The firm had revenue of $340.80 million during the quarter, compared to analyst estimates of $311.84 million. Insulet had a return on equity of 18.19% and a net margin of 1.35%. On average, research analysts anticipate that Insulet Co. will post 0.87 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on PODD. Robert W. Baird raised their price target on Insulet from $315.00 to $340.00 in a report on Monday, December 12th. Jefferies Financial Group began coverage on shares of Insulet in a research note on Wednesday, October 12th. They issued a “hold” rating and a $260.00 target price on the stock. Morgan Stanley raised their price target on shares of Insulet from $300.00 to $320.00 and gave the company an “equal weight” rating in a research report on Friday, January 6th. Citigroup increased their target price on Insulet from $270.00 to $330.00 in a research note on Monday, December 12th. Finally, StockNews.com upgraded Insulet from a “sell” rating to a “hold” rating in a research note on Wednesday, November 9th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $309.23.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.
- Get a free copy of the StockNews.com research report on Insulet (PODD)
- General Electric Stock, The Sum of All Parts Strategy is Paying Off
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.